Unique Features

  • Management of Postmenopausal Osteoporosis
  • Prediction of long-term skeletal response to anti-resorptive therapies, e.g. HRT, bisphosphonates
  • Increase in patient motivation and compliance
  • Assessment of Bone Resorption in Patients
  • With metabolic bone disease, e.g. hyperparathyroidism, Paget´s disease, osteodystrophy
  • Receiving prolonged glucocorticoid therapy
  • A reference marker for osteoporosis management as indicated by IOF, IFCC and NBHA
  • Easy to perform – one step incubation
  • Excellent correlation with automated methods
  • A complete assay panel supporting bone disease management

Product Description
The Serum CrossLaps® (CTX-I) ELISA is an enzyme immunological test for the quantification of degradation products of C-terminal telopeptides of Type I collagen in human serum and plasma. For research use only.

The Serum CrossLaps® (CTX-I) ELISA assay is intended for in-vitro diagnostic use as an indication of human bone resorption and may be used as an aid in:

1. Monitoring bone resorption changes of:
a) Anti-resorptive therapies in postmenopausal women1, 2:
Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
Bisphosphonate therapies
b) Anti-resorptive therapies in individuals diagnosed with osteopaenia:
Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
Bisphosphonate therapies

2. Predicting skeletal response (Bone Mineral Density) in postmenopausal women undergoing
anti-resorptive therapies:
a) Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
b) Bisphosphonate therapies

McClung MR et al., Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013 Jan;24(1):227-35

Stoch SA et al., Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics–results from single oral dose studies in healthy volunteers. Br J Clin Pharmacol. 2013 May;75(5):1240-54

Vasikaran SD et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2010; 22(2):391-420.